Colorado needs to take action on skyrocketing drug prices | OPINION
The pharmaceutical industry is one of the most opaque industries in the country. Drugs are arbitrarily priced, profits are maximized, industry players point fingers at each other to deflect blame and patients suffer at the expense of corporate greed.
In 2024, more than half of Coloradans reported being worried about being able to afford their prescription drugs. Our legislators have taken several steps to improve affordability and patient access to prescription drugs, but the Prescription Drug Affordability Board (PDAB) is the only tool the state has that evaluates and addresses the root causes of skyrocketing drug prices.
Last year, the Board ruled Enbrel, Cosentyx and Stelara as "unaffordable" for Colorado consumers. This year, they have the opportunity to set an upper payment limit (UPL) on all three drugs and bring savings to Colorado consumers. The board is currently working through the upper payment limit process for Enbrel, which is expected to be announced on Friday.
In Colorado, Enbrel patients with commercial insurance spent more than
Taking into account the average Enbrel patient is paying
The board is considering setting the UPL at Enbrel's CMS
According to AHIP, more than 24% of all commercial health plan premiums go toward prescription drug costs. The effect of an upper payment limit will be far-reaching; not only will it have an effect on patients' out-of-pocket costs, but it should also effect consumer health insurance premiums.
At the same time, Big Pharma has worked hard to prevent the critical work of the board. They have threatened to pull out of the state, they have been running a major astroturfing campaign through third-party organizations, they have claimed they won't be able to research and develop new drugs and they have sued the state of Colorado.
This is propaganda. They are not telling the truth. Big Pharma routinely spends more on direct-to-consumer ads than on the research and development of new drugs. Last year, Big Pharma spent
They are not worried about funding research and development of new drugs; they're trying to protect their profits.
Big Pharma is one of the only players in the health care industry that has been allowed to operate unchecked. They have been allowed to set prices in
Families are struggling to afford their everyday necessities, and we must use every tool available to reduce health care spending for Colorado families. Our state budget is tight, and recent changes at the federal level are projected to increase premiums on the Colorado state marketplace by up to 38% in 2026. The PDAB can save our state health plans money and shield consumers from bearing the full weight of these projected premium increases.
We have been paying too much for prescription drugs for far too long. Colorado's PDAB is paving the way in setting the first upper payment limit in the country, ensuring Colorado patients can afford their drugs. We hope they pursue upper payment limits for Cosentyx and Stelara in the coming months, so Colorado can capture more savings.
No family should avoid filling their prescription because of the cost, and the state's Prescription Drug Affordability Board is a crucial part of reducing health care costs for Coloradans.
The post Colorado needs to take action on skyrocketing drug prices | OPINION appeared first on Colorado Politics.


FEDERAL REVENUE AND DISTRIBUTIONAL IMPACTS OF LIMITING THE TAX EXCLUSION FOR EMPLOYER-SPONSORED HEALTH INSURANCE PREMIUMS
Investigators at Hunan University Have Reported New Data on Chronic Disease (Does chronic disease coverage for outpatient care affect healthcare utilization and expenditures in China? Evidence from an administrative claim dataset): Disease Attributes – Chronic Disease
Advisor News
- What will Democrats in Congress do about healthcare and retirement?
- Election results cloud retirement legislation outlook, experts say
- Planning for the missing chapter
- Semi-retirement: helping clients balance flexibility with financial security
- The 6X Formula for leveraging content marketing with AI
More Advisor NewsAnnuity News
- Jackson Launches Direct-to-Consumer Annuity Offering
- Global Atlantic launches ForeIncome Flex
- Athene CEO criticizes offshore reinsurance, risk-taking by competitors
- DOL, trade groups, state AGs file briefs supporting Alcoa in PRT lawsuit
- John Hancock launches new fixed indexed annuity suite
More Annuity NewsHealth/Employee Benefits News
- What will Democrats in Congress do about healthcare and retirement?
- Forms, phone calls and portals: The hidden work that keeps American institutions functioning burdens parents most
- Health Plans Expect Double-Digit Premium Increases Again in 2027
- Best’s Special Report: Rising Costs Could Offset AI-Driven Efficiency Gains at US Health Insurers
- Free Medicare counseling provided through LTADD
More Health/Employee Benefits NewsLife Insurance News
- Navigating delayed death certificates: A guide for life insurance advisors
- Jackson Launches Direct-to-Consumer Annuity Offering
- Best’s Market Segment Report: AM Best Maintains Stable Outlook on New Zealand’s Non-Life Insurance Segment
- AM Best Affirms Credit Ratings of Fubon Insurance Vietnam Co., Ltd.
- Three lawsuits put life insurers’ cost-of-insurance practices under scrutiny
More Life Insurance News